Shcherbakov A B, Guseva N G, Mach E S
Ter Arkh. 1985;57(5):141-4.
Twenty patients with systemic scleroderma (SSD) and Raynaud's syndrome (RS) received 30-80 mg of corinfar, a blocker of calcium channels, during 14 days. Seventeen patients responded to the treatment. The clinical effect was manifested by a decrease in the rate, duration and intensity of RS attacks. Side effects were recorded in 6 patients, but the drug was discontinued only in 2 patients because of the allergic reactions. During treatment, the patients showed an increase in tissue blood flow parameters. Corinfar may be regarded a drug of choice in the treatment of marked RS in SSD.
20例系统性硬化症（SSD）合并雷诺氏综合征（RS）患者在14天内接受了30 - 80毫克的可立安（一种钙通道阻滞剂）治疗。17例患者对治疗有反应。临床疗效表现为雷诺氏综合征发作的频率、持续时间和强度降低。6例患者记录到有副作用，但仅2例患者因过敏反应而停药。治疗期间，患者的组织血流参数有所增加。可立安可被视为治疗系统性硬化症中显著雷诺氏综合征的首选药物。
